Cardinal sees no retail opposition to Bergen merger; regional antitrust issues are not a concern, firm says.
CARDINAL CLAIMS RETAIL CUSTOMER SUPPORT FOR BERGEN MERGER, John Kane told the Bear Stearns health care conference in New York City on Sept. 9. "We have gotten tremendously high customer acceptance and customer affidavit support" for the merger of Cardinal Health and Bergen Brunswig to create the largest drug wholesaler, Kane maintained. "I know the [Federal Trade Commission] is calling customers and we are surprised that the response we've had is much higher than we thought it would be." Cardinal and Bergen announced the merger in late August ("The Pink Sheet" Sept. 1, p. 3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth